Pangea Biomed, a startup developing the Enlight cancer response prediction platform, announced the beginning of a pilot collaboration with the Knight Cancer Institute at Oregon Health and Science University.
Research published in Communications Biology demonstrates the potential of Aqtual’s proprietary platform that evaluates gene regulation, epigenetics, and transcriptomics by analyzing previously unexplored cfDNA fragments found in blood, opening the door to novel clinical applications in almost every major disease area.
